Glaucoma Medications

Glaucoma is one of the leading causes of irreversible vision loss worldwide, but the right medication plan can help slow its progression and preserve your sight. At Greenwich Ophthalmology Associates, our glaucoma specialists work closely with patients across the greater NY/CT region to find the most effective and well-tolerated eye drop regimen for each individual. Most glaucoma treatment begins with prescription eye drops designed to lower intraocular pressure (IOP), the primary modifiable risk factor for optic nerve damage. Understanding how these medications work, what to expect from each class, and how to use them correctly gives you an active role in protecting your long-term vision.

Several classes of medicated eye drops are available to lower eye pressure, and each works through a different mechanism. Our glaucoma specialists select or combine these medications based on your pressure targets, overall health, and how well you tolerate treatment.

Every glaucoma eye drop aims to reduce intraocular pressure to a level that slows or halts optic nerve damage. Your target pressure is personalized and depends on the severity of your glaucoma, baseline pressure readings, and the presence of other risk factors such as family history or thin corneas. Reaching and maintaining this target is the single most important step in slowing the rate of glaucoma progression.

The primary medication classes used today include prostaglandin analogs, beta-blockers, alpha-adrenergic agonists, carbonic anhydrase inhibitors (CAIs), and rho kinase inhibitors. Each class lowers pressure through a distinct pathway, either by reducing the amount of fluid (aqueous humor) the eye produces or by improving how fluid drains out of the eye. Your drop regimen may include one class or a combination of two or more, depending on how your eye responds.

Rho kinase inhibitors, such as netarsudil (Rhopressa), represent a newer approach that works directly on the trabecular meshwork, the eye's primary drainage tissue, to improve outflow. Latanoprostene bunod (Vyzulta) combines a prostaglandin analog with a nitric oxide-donating component to lower pressure through two complementary pathways. These options can be especially helpful for patients who need additional pressure reduction beyond what older classes provide.

We consider several factors before prescribing a glaucoma drop, including your current eye pressure, the type of glaucoma you have, any systemic health conditions, and your tolerance of preservatives found in some formulations. Cost, insurance coverage, and the number of daily doses also play a role. The goal is always to choose the simplest, most effective regimen that fits your daily life.

Alpha-adrenergic agonists offer a dual mechanism that both decreases aqueous humor production and increases fluid outflow. This makes them a versatile option for combination therapy or for patients who cannot tolerate other classes.

These drops stimulate alpha-2 receptors in the ciliary body, which signals the eye to produce less aqueous humor. At the same time, they promote drainage through the uveoscleral outflow pathway. The combined effect typically lowers IOP by approximately 20 to 25 percent. This two-pronged action can be particularly useful for patients who are close to their target pressure but need an extra reduction.

Brimonidine (Alphagan P) is the most widely used alpha-agonist for chronic glaucoma management. Its formulation uses the preservative Purite, which is gentler on the ocular surface than benzalkonium chloride. Apraclonidine (Iopidine) is primarily used for short-term pressure control, such as after laser procedures, rather than long-term daily therapy.

Allergic reactions to brimonidine, including redness, itching, and swelling of the eyelids, can develop in a small percentage of patients, sometimes after months of use. If an allergy develops, we may switch you to a different medication class. Brimonidine should be used with caution in very young children due to the risk of central nervous system depression, though this is not a concern for adult patients.